Antibody reactivity to synthetic peptides representing the principal neutralizing determinant of HIV-1 in mouse strains following repeated immunization with recombinant gp160

Exp Clin Immunogenet. 1993;10(3):168-75.

Abstract

The third variable region (V3) of the HIV-1 gp120 envelope molecule appears to represent a target for naturally occurring neutralizing antibodies in HIV-1-infected individuals. In this report, we examined the extent of antibody cross-reactivity to a panel of V3-based synthetic peptides in six inbred strains of mice following repeated immunization with a baculovirus-derived recombinant gp160 (rgp160) preparation formulated with alum. The amino acid sequence of the rgp160 used in these immunizations was based upon the HIV-1 IIIB (LAI) isolate. Following five injections with rgp160, all six strains developed antibodies to the homologous IIIB-based V3 peptides, designated 304-321 and RP135. However, antibody cross-reactivity to the other nonhomologous V3 peptides was either undetectable or limited among the strains of mice examined. No in vitro neutralizing activity against HIV-1 was observed in sera from any of the six inbred strains of mice that were examined. These results suggest that repeated immunization of mouse strains with a rgp160/alum formulation leads to nonneutralizing antibodies directed against the V3 region which remain predominantly type specific.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibody Formation
  • Cross Reactions / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • HIV Antigens / immunology*
  • HIV-1 / immunology*
  • Humans
  • Immunization
  • Immunoglobulin Variable Region / immunology*
  • Infant
  • Mice
  • Mice, Inbred Strains
  • Molecular Sequence Data
  • Recombinant Fusion Proteins

Substances

  • HIV Antigens
  • Immunoglobulin Variable Region
  • Recombinant Fusion Proteins